UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

BMC cancer, 2021-11, Vol.21 (1), p.1204-1204, Article 1204

2021

Volltextzugriff (PDF)

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

BMC cancer, 2021-05, Vol.21 (1), p.578-578, Article 578

2021

Volltextzugriff (PDF)

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Annals of oncology, 2018-12, Vol.29 (12), p.2334-2340

2018

Volltextzugriff (PDF)

Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data

Critical reviews in oncology/hematology, 2018-12, Vol.132, p.138-144

2018

Volltextzugriff (PDF)

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

Journal of medical case reports, 2016-06, Vol.10 (1), p.178-178, Article 178

2016

Volltextzugriff (PDF)

The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy

Breast (Edinburgh), 2018-02, Vol.37, p.114-118

2018

Volltextzugriff (PDF)

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

ESMO open, 2023-12, Vol.8 (6), p.102041-102041, Article 102041

2023

Volltextzugriff (PDF)

A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)

Annals of oncology, 2018-10, Vol.29, p.viii89-viii89

2018

Volltextzugriff (PDF)

Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Annals of oncology, 2018-10, Vol.29, p.viii57-viii57

2018

Volltextzugriff (PDF)

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study

ESMO open, 2021-08, Vol.6 (4), p.100207-100207, Article 100207

2021

Volltextzugriff (PDF)

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

The New England journal of medicine, 2020-02, Vol.382 (7), p.597-609

2020

Volltextzugriff (PDF)

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia

Leukemia, 2010-05, Vol.24 (5), p.1052-1055

2010

Volltextzugriff (PDF)

The Place of Extensive Surgery in Locoregional Recurrence and Limited Metastatic Disease of Breast Cancer: Preliminary Results

BioMed research international, 2015-01, Vol.2015 (2015), p.1-7

2015

Volltextzugriff (PDF)

341PFinal results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

385TiPRIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

224PA critical appraisal of quality indicators of breast cancer treatment in Belgium

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results

Acta clinica belgica (English ed. Online), 2020-03, Vol.75 (2), p.128-135

2020

Volltextzugriff (PDF)

281TiPA phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

183TiPNeoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Abstract P6-17-32: Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-32

2019

Volltextzugriff (PDF)

Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

Clinical epidemiology, 2023-01, Vol.15, p.559-568

2023

Volltextzugriff (PDF)

Abstract OT1-03-03: STEM: SFX-01 in the treatment and evaluation of metastatic breast cancer

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT1-03-03-OT1-03-03

2019

Volltextzugriff (PDF)

1 – 25 von 80

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(72)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Safety of systemic anti-cancer treatment in oncology patients with non-severe COVID-19: a cohort study

Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer

Prevalence of pathogenic variants and variants of unknown significance in patients at high risk of breast cancer: A systematic review and meta-analysis of gene-panel data

Tumor lysis syndrome following trastuzumab and pertuzumab for metastatic breast cancer: a case report

The advantages of hypnosis intervention on breast cancer surgery and adjuvant therapy

Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study

A phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)

Neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia

The Place of Extensive Surgery in Locoregional Recurrence and Limited Metastatic Disease of Breast Cancer: Preliminary Results

341PFinal results of the STEM trial: SFX-01 in the treatment and evaluation of ER+ Her2- metastatic breast cancer (mBC)

385TiPRIBOB: A study on the efficacy and safety of ribociclib in combination with letrozole in older women (≥70 years) with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior systemic therapy for advanced disease

224PA critical appraisal of quality indicators of breast cancer treatment in Belgium

A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer: The International Consortium for Health Outcomes Measurement (ICHOM) Initiative

333PRibociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase IIIb CompLEEment-1 trial

Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results

281TiPA phase Ib/II study of durvalumab combined with dose-dense EC in neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers (B-IMMUNE)

183TiPNeoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer: The phase II NeoRHEA trial

Abstract P6-17-32: Impact of the line of treatment on progression-free survival in patients treated with T-DM1 for metastatic breast cancer

Machine Learning Algorithm to Estimate Distant Breast Cancer Recurrence at the Population Level with Administrative Data

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Abstract OT1-03-03: STEM: SFX-01 in the treatment and evaluation of metastatic breast cancer

Suchergebnisse filtern